Điều trị tiêm tĩnh mạch dài hạn bệnh Pompe bằng α-Glucosidase tái tổ hợp từ sữa người qua phương pháp chuyển gen
Tóm tắt
Từ khóa
#Pompe disease #transgenic animals #recombinant human α-glucosidase #enzyme replacement therapy #lysosomal storage disorder #genetic mutation #cardiac hypertrophy #long-term treatment #muscle regeneration #infantile Pompe diseaseTài liệu tham khảo
Janne J, Alhonen L, Hyttinen JM, Peura T, Tolvanen M, Korhonen VP. Transgenic bioreactors. Biotechnol Annu Rev. 1998;4:55–74
Simons JP, Wilmut I, Clark AJ, Archibald AL, Bishof JO, Lathe R. Gene transfer into sheep. Biotechnology. 1988;6:113–120
McKee C, Gibson A, Dalrymple M, Emslie L, Garner I, Cottingham I. Production of biologically active salmon calcitonin in the milk of transgenic rabbits. Nat Biotechnol. 1998;16:647–651
Niemann H, Halter R, Carnwath JW, Herrmann D, Lemme E, Paul D. Expression of human blood clotting factor VIII in the mammary gland of transgenic sheep. Transgenic Res. 1999;8:237–247
Paleyanda RK, Velander WH, Lee TK, et al. Transgenic pigs produce functional human factor VIII in milk. Nat Biotechnol. 1997;15:971–975
Van Berkel PH, Welling MM, Geerts M, et al. Large scale production of recombinant human lactoferrin in the milk of transgenic cows. Nat Biotechnol. 2002;20:484–487
Lu W, Mant T, Levy JH, Bailey JM. Pharmacokinetics of recombinant transgenic antithrombin in volunteers. Anesth Analg. 2000;90:531–534
Carver AS, Dalrymple MA, Wright G, et al. Transgenic livestock as bioreactors: stable expression of human alpha-1-antitrypsin by a flock of sheep. Biotechnology. 1993;11:1263–1270
Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet. 2000;356:397–398
van den Hout JMP, Hop W, van Diggelen OP, et al. The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112:332–340
Hirschhorn R, Reuser AJJ. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet A, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001:3389–3420
Slonim AE, Bulone L, Ritz S, Goldberg T, Chen A, Martiniuk F. Identification of two subtypes of infantile acid maltase deficiency. J Pediatr. 2000;137:283–285
Ausems MG, Verbiest J, Hermans MP, et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet. 1999;7:713–716
Martiniuk F, Chen A, Mack A, et al. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet. 1998;79:69–72
Van der Ploeg AT, Van der Kraaij AM, Willemsen R, et al. Rat heart perfusion as model system for enzyme replacement therapy in glycogenosis type II. Pediatr Res. 1990;28:344–347
Van der Ploeg AT, Kroos MA, Willemsen R, Brons NH, Reuser AJ. Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice. J Clin Invest. 1991;87:513–518
Bijvoet AG, Kroos MA, Pieper FR, et al. Recombinant human acid alpha-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice. Hum Mol Genet. 1998;7:1815–1824
Bijvoet AG, Van Hirtum H, Kroos MA, et al. Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum Mol Genet. 1999;8:2145–2153
Hoefsloot LH, Hoogeveen-Westerveld M, Kroos MA, Van Beeumen J, Reuser AJ, Oostra BA. Primary structure and processing of lysosomal alpha-glucosidase: homology with the intestinal sucrase-isomaltase complex. EMBO J. 1988;7:1697–1704
Martiniuk F, Mehler M, Tzall S, Meredith G, Hirschhorn R. Sequence of the cDNA and 5′-flanking region for human acid alpha-glucosidase, detection of an intron in the 5′ untranslated leader sequence, definition of 18-bp polymorphisms, and differences with previous cDNA and amino acid sequences. DNA Cell Biol. 1990;9:85–94
Hoefsloot LH, Hoogeveen-Westerveld M, Reuser AJ, Oostra BA. Characterization of the human lysosomal alpha-glucosidase gene. Biochem J. 1990;272:493–497
Fuller M, Van der Ploeg A, Reuser AJ, Anson DS, Hopwood JJ. Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase. Eur J Biochem. 1995;234:903–909
Bijvoet AG, Kroos MA, Pieper FR, et al. Expression of cDNA-encoded human acid alpha-glucosidase in milk of transgenic mice. Biochim Biophys Acta. 1996;1308:93–96
Reuser AJ, Koster JF, Hoogeveen A, Galjaard H. Biochemical, immunological, and cell genetic studies in glycogenosis type II. Am J Hum Genet. 1978;30:132–143
Hermans MM, Kroos MA, Smeitink JA, van der Ploeg AT, Kleijer WJ, Reuser AJ. Glycogen storage disease type II: genetic and biochemical analysis of novel mutations in infantile patients from Turkish ancestry. Hum Mutat. 1998;11:209–215
Reuser AJ, Kroos M, Oude Elferink RP, Tager JM. Defects in synthesis, phosphorylation, and maturation of acid alpha-glucosidase in glycogenosis type II. J Biol Chem. 1985;260:8336–8341
Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072–1083
Devereux RB, Casale PN, Kligfield P, et al. Performance of primary and derived M-mode echocardiographic measurements for detection of left ventricular hypertrophy in necropsied subjects and in patients with systemic hypertension, mitral regurgitation and dilated cardiomyopathy. Am J Cardiol. 1986;57:1388–1393
Piper MC, Darrah J. Motor Assessment of the Developing Infant. Philadelphia, PA: WB Saunders Company; 1994
Bayley N. Bayley Scales of Infant Development. 2nd ed. San Antonio, TX: Harcourt Brace & Company; 1993
Van Hove JL, Yang HW, Wu JY, Brady RO, Chen YT. High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease. Proc Natl Acad Sci U S A. 1996;93:65–70
Hermans MM, De Graaff E, Kroos MA, et al. The effect of a single base pair deletion (delta T525) and a C1634T missense mutation (pro545leu) on the expression of lysosomal alpha-glucosidase in patients with glycogen storage disease type II. Hum Mol Genet. 1994;3:2213–2218
Winkel LPF, Kamphoven JHJ, Van den Hout JMP, et al. Morphological changes in muscle tissue of patients with infantile Pompe’s disease receiving enzyme replacement therapy. Muscle Nerve. 2003;27:743–751
Vogel M, Staller W, Buhlmeyer K. Left ventricular myocardial mass determined by cross-sectional echocardiography in normal newborns, infants and children. Pediatr Cardiol. 1991;12:143–149
Wisselaar HA, Kroos MA, Hermans MM, Van Beeumen J, Reuser AJ. Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation. J Biol Chem. 1993;268:2223–2231
Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med. 2001;3:132–138
Eng C, Guffon N, Wilcox W, et al. Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry’s disease. N Engl J Med. 2001;345:9–16
Eng CM, Banikazemi M, Gordon RE, et al. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet. 2001;68:711–722
Grabowski GA, Leslie N, Wenstrup R. Enzyme therapy for Gaucher disease: the first 5 years. Blood Rev. 1998;12:115–133
Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001;344:182–188
Schiffmann R, Kopp JB, Austin HA, et al. Enzyme replacement therapy in Fabry disease. A randomized controlled trial. JAMA. 2001;285:2743–2749
Winkel LPF, Van den Hout JMP, Kamphoven JHJ, et al. Preliminary findings in patients with juvenile Pompe’s disease treated with recombinant human alpha-glucosidase from rabbit milk. Am J Hum Genet. 2001;S96:674
Schiffmann R, Murray GJ, Treco D, et al. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A. 2000;97:365–370
Sands MS, Vogler CA, Ohlemiller KK, et al. Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII. J Biol Chem. 2001;276:43160–43165